Q2 Earnings Forecast for electroCore Issued By HC Wainwright

electroCore, Inc. (NASDAQ:ECOR) – Analysts at HC Wainwright upped their Q2 2025 earnings estimates for shares of electroCore in a research note issued to investors on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.19). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.60) EPS.

electroCore Price Performance

Shares of electroCore stock opened at $14.52 on Friday. The firm has a market cap of $95.18 million, a price-to-earnings ratio of -7.93 and a beta of 0.57. The stock’s 50-day moving average is $11.51 and its 200-day moving average is $8.12. electroCore has a one year low of $5.25 and a one year high of $17.84.

Institutional Investors Weigh In On electroCore

Several institutional investors have recently bought and sold shares of ECOR. HighTower Advisors LLC bought a new position in shares of electroCore during the 3rd quarter worth approximately $255,000. International Assets Investment Management LLC boosted its holdings in electroCore by 27.9% during the second quarter. International Assets Investment Management LLC now owns 67,820 shares of the company’s stock worth $436,000 after purchasing an additional 14,800 shares during the last quarter. Renaissance Technologies LLC grew its position in electroCore by 3.4% in the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after purchasing an additional 2,270 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in electroCore by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after buying an additional 5,951 shares during the last quarter. Institutional investors own 26.74% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.